1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co.,Ltd.

603669.SS
Lionco Pharmaceutical Group Co.,Ltd.CN flagShanghai Stock Exchange
5.97
CNY
-0.15
- -
4.25BMarket Cap

Total Valuation

Lionco Pharmaceutical Group Co.,Ltd. carries a market capitalization of 4.25B, placing it among publicly traded companies globally. Its enterprise value stands at 3.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.25B
Enterprise Value3.92B

Share Statistics

Lionco Pharmaceutical Group Co.,Ltd. currently has 721.24M shares outstanding.

Shares Outstanding721.24M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 9.51, and the price-to-book ratio stands at 10.29.

PE RatioN/A
PS Ratio9.51
PB Ratio10.29
P/TBV Ratio6.12
P/FCF Ratio2,071.91
P/OCF RatioN/A

Enterprise Valuation

EV / Sales9.56
EV / EBITDAN/A
EV / EBITN/A
EV / FCF100.40

Financial Position

Lionco Pharmaceutical Group Co.,Ltd. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.39, indicating elevated leverage, while an interest coverage ratio of -1.85 demonstrates limited ability to service its debt obligations.

Current Ratio2.86
Quick Ratio1.26
Debt / Equity37.39
Debt / EBITDA-4.11
Interest Coverage-1.85

Financial Efficiency

Return on Equity (ROE)-28.54
Return on Assets (ROA)-9.49
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover6.14

Taxes

Income Tax3.59M
Effective Tax RateN/A

Stock Price Statistics

Lionco Pharmaceutical Group Co.,Ltd.'s stock has gained approximately 5.10563% over the past 52 weeks. The 50-day moving average sits at 4.67, while the 200-day moving average is 4.86.

Beta (5Y)N/A
52-Week Price Change5.10563%
50-Day Moving Average4.67
200-Day Moving Average4.86
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Lionco Pharmaceutical Group Co.,Ltd. generated 409.91M in revenue and converted that into -126.10M in net income, yielding earnings per share of -0.17. EBITDA reached -66.76M, while operating income came in at -66.76M.

Revenue409.91M
Gross Profit144.97M
Operating Income-66.76M
Pretax Income-122.50M
Net Income-126.10M
EBITDA-66.76M
EBIT-66.76M
Earnings Per Share (EPS)-0.17

Balance Sheet

Lionco Pharmaceutical Group Co.,Ltd. holds 251.24M in cash and equivalents against 274.48M in total debt, resulting in a net debt position of 30.28M. Total book value stands at 378.83M, with working capital of 372.52M providing operational flexibility.

Cash & Cash Equivalents251.24M
Total Debt274.48M
Net Debt30.28M
Equity (Book Value)378.83M
Book Value Per Share0.52
Working Capital372.52M

Cash Flow

After subtracting -1.88M in capital expenditures, free cash flow totaled -1.88M - equivalent to 0.00 per share.

Operating Cash FlowN/A
Capital Expenditures-1.88M
Free Cash Flow-1.88M
FCF Per Share0.00

Margins

Lionco Pharmaceutical Group Co.,Ltd. operates with a gross margin of 35.37, reflecting its pricing power and cost economics. The operating margin of -16.29 and net profit margin of -30.76 provide insight into operational efficiency.

Gross Margin35.37
Operating Margin-16.29
Pretax Margin-29.89
Profit Margin-30.76
EBITDA Margin-16.29

Dividends & Yields

The company's payout ratio of -4.39 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.01
Dividend YieldN/A
Payout Ratio-4.39
Shareholder Yield5.89
FCF Yield0.05

Stock Splits

Lionco Pharmaceutical Group Co.,Ltd.'s most recent stock split took place on May 26, 2020 with a 5:7 split ratio.

Last Split Date5/26/2020
Split Ratio5:7

Scores

Lionco Pharmaceutical Group Co.,Ltd. posts an Altman Z-Score of 5.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.05